Krka d. d - Asset Resilience Ratio
Krka d. d (KRK) has an Asset Resilience Ratio of 7.73% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Krka d. d for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Krka d. d's Asset Resilience Ratio has changed over time. See shareholders equity of Krka d. d for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Krka d. d's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see KRK market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł229.29 Million | 7.73% |
| Total Liquid Assets | zł229.29 Million | 7.73% |
Asset Resilience Insights
- Limited Liquidity: Krka d. d maintains only 7.73% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Krka d. d Industry Peers by Asset Resilience Ratio
Compare Krka d. d's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 0.96% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
Annual Asset Resilience Ratio for Krka d. d (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Krka d. d.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 8.58% | zł244.34 Million ≈ $67.25 Million |
zł2.85 Billion ≈ $784.09 Million |
+6.04pp |
| 2023-12-31 | 2.53% | zł70.02 Million ≈ $19.27 Million |
zł2.76 Billion ≈ $760.77 Million |
+0.65pp |
| 2022-12-31 | 1.89% | zł50.70 Million ≈ $13.95 Million |
zł2.69 Billion ≈ $739.64 Million |
-4.18pp |
| 2021-12-31 | 6.07% | zł153.96 Million ≈ $42.37 Million |
zł2.54 Billion ≈ $698.41 Million |
+5.67pp |
| 2020-12-31 | 0.40% | zł8.97 Million ≈ $2.47 Million |
zł2.24 Billion ≈ $615.25 Million |
+0.30pp |
| 2019-12-31 | 0.10% | zł2.17 Million ≈ $598.32K |
zł2.18 Billion ≈ $601.24 Million |
-0.05pp |
| 2018-12-31 | 0.15% | zł2.92 Million ≈ $803.63K |
zł1.99 Billion ≈ $546.32 Million |
+0.64pp |
| 2017-12-31 | -0.50% | zł-9.54 Million ≈ $-2.63 Million |
zł1.92 Billion ≈ $528.17 Million |
-0.50pp |
| 2016-12-31 | 0.00% | zł77.00K ≈ $21.19K |
zł1.91 Billion ≈ $526.08 Million |
0.00pp |
| 2015-12-31 | 0.00% | zł79.00K ≈ $21.74K |
zł1.81 Billion ≈ $497.92 Million |
-0.03pp |
| 2014-12-31 | 0.03% | zł575.00K ≈ $158.25K |
zł1.80 Billion ≈ $494.21 Million |
-0.01pp |
| 2013-12-31 | 0.05% | zł792.00K ≈ $217.97K |
zł1.76 Billion ≈ $484.35 Million |
+0.00pp |
| 2012-12-31 | 0.04% | zł679.00K ≈ $186.87K |
zł1.63 Billion ≈ $447.70 Million |
+0.00pp |
| 2011-12-31 | 0.04% | zł602.00K ≈ $165.68K |
zł1.53 Billion ≈ $422.19 Million |
0.00pp |
| 2010-12-31 | 0.04% | zł653.00K ≈ $179.72K |
zł1.49 Billion ≈ $409.58 Million |
-- |
About Krka d. d
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company's prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolis… Read more